Hypoxia or low oxygen concentration in tumor microenvironment has widespread effects ranging from altered angiogenesis and lymphangiogenesis, tumor metabolism, growth, and therapeutic resistance in different cancer types. A large number of these effects are mediated by the transcription factor hypoxia inducible factor 1⍺ (HIF-1⍺) which is activated by hypoxia. HIF1⍺ induces glycolytic genes and reduces mitochondrial respiration rate in hypoxic tumoral regions through modulation of various cells in tumor microenvironment like cancer-associated fibroblasts. Immune evasion driven by HIF-1⍺ further contributes to enhanced survival of cancer cells. By altering drug target expression, metabolic regulation, and oxygen consumption, hypoxia leads to enhanced growth and survival of cancer cells. Tumor cells in hypoxic conditions thus attain aggressive phenotypes and become resistant to chemo- and radio- therapies resulting in higher mortality. While a number of new therapeutic strategies have succeeded in targeting hypoxia, a significant improvement of these needs a more detailed understanding of the various effects and molecular mechanisms regulated by hypoxia and its effects on modulation of the tumor vasculature. This review focuses on the chief hypoxia-driven molecular mechanisms and their impact on therapeutic resistance in tumors that drive an aggressive phenotype.
Impact statement
Hypoxia contributes to tumor aggressiveness and promotes growth of many solid tumors that are often resistant to conventional therapies. In order to achieve successful therapeutic strategies targeting different cancer types, it is necessary to understand the molecular mechanisms and signaling pathways that are induced by hypoxia. Aberrant tumor vasculature and alterations in cellular metabolism and drug resistance due to hypoxia further confound this problem. This review focuses on the implications of hypoxia in an inflammatory TME and its impact on the signaling and metabolic pathways regulating growth and progression of cancer, along with changes in lymphangiogenic and angiogenic mechanisms. Finally, the overarching role of hypoxia in mediating therapeutic resistance in cancers is discussed.
SemenzaGL.Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell2004;
5:405–6
4.
BayerCShiKAstnerSTMafteiC-AVaupelP.Acute versus chronic hypoxia: why a simplified classification is simply not enough. Int J Radiat Oncol Biol Phys2011;
80:965–8
5.
SemenzaGL.HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med2002;
8:S62–7
6.
SaxenaKJollyMK.Acute vs. chronic vs. cyclic hypoxia: their differential dynamics, molecular mechanisms, and effects on tumor progression. Biomolecules2019;
9:339
7.
SemenzaGL.The hypoxic tumor microenvironment: a driving force for breast cancer progression. Biochim Biophys Acta2016;
1863:382–91
8.
SerockiMBartoszewskaSJanaszak-JasieckaAOchockaRJCollawnJFBartoszewskiR.miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target. Angiogenesis2018;
21:183–202
9.
HuCJWangLYChodoshLAKeithBSimonMC.Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol2003;
23:9361–74
10.
ParkBKPaikYHParkJYParkKHBangSParkSWChungJBParkYNSongSY.The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma. Am J Clin Oncol2006;
29:138–42
11.
RosmorducOHoussetC.Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis2010;
30:258–70
12.
HolmquistLJogiAPahlmanS.Phenotypic persistence after reoxygenation of hypoxic neuroblastoma cells. Int J Cancer2005;
116:218–25
13.
Holmquist-MengelbierLFredlundELofstedtTNogueraRNavarroSNilssonHPietrasAVallon-ChristerssonJBorgAGradinKPoellingerLPahlmanS.Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell2006;
10:413–23
14.
KoivunenPHirsilaMGunzlerVKivirikkoKIMyllyharjuJ.Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem2004;
279:9899–904
15.
BartoszewskiRMoszynskaASerockiMCabajAPoltenAOchockaRDell’ItaliaLBartoszewskaSKroliczewskiJDabrowskiMCollawnJF.Primary endothelial cell-specific regulation of hypoxia-inducible factor (HIF)-1 and HIF-2 and their target gene expression profiles during hypoxia. FASEB J2019;
33:7929–41
16.
KohMYLemosRJr.LiuXPowisG.The hypoxia-associated factor switches cells from HIF-1alpha- to HIF-2alpha-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res2011;
71:4015–27
17.
LinQCongXYunZ.Differential hypoxic regulation of hypoxia-inducible factors 1alpha and 2alpha. Mol Cancer Res2011;
9:757–65
18.
LuoWZhongJChangRHuHPandeyASemenzaGL.Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxia-inducible factor (HIF)-1alpha but not HIF-2alpha. J Biol Chem2010;
285:3651–63
19.
BentoCFFernandesRRamalhoJMarquesCShangFTaylorAPereiraP.The chaperone-dependent ubiquitin ligase CHIP targets HIF-1alpha for degradation in the presence of methylglyoxal. PLoS One2010;
5:e15062
20.
Kochan-JamrozyKKroliczewskiJMoszynskaACollawnJFBartoszewskiR.miRNA networks modulate human endothelial cell adaptation to cyclic hypoxia. Cell Signal2019;
54:150–60
21.
ToffoliSRoegiersAFeronOVan SteenbruggeMNinaneNRaesMMichielsC.Intermittent hypoxia is an angiogenic inducer for endothelial cells: role of HIF-1. Angiogenesis2009;
12:47–67
22.
MartinivePDefresneFQuaghebeurEDaneauGCrokartNGregoireVGallezBDessyCFeronO.Impact of cyclic hypoxia on HIF-1alpha regulation in endothelial cells – new insights for anti-tumor treatments. FEBS J2009;
276:509–18
23.
ToffoliSFeronORaesMMichielsC.Intermittent hypoxia changes HIF-1alpha phosphorylation pattern in endothelial cells: unravelling of a new PKA-dependent regulation of HIF-1alpha. Biochim Biophys Acta2007;
1773:1558–71
24.
VerduzcoDLloydMXuLIbrahim-HashimABalagurunathanYGatenbyRAGilliesRJ.Intermittent hypoxia selects for genotypes and phenotypes that increase survival, invasion, and therapy resistance. PLoS One2015;
10:e0120958–e58
25.
AmmiranteMShalapourSKangYJamiesonCAKarinM.Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci U S A2014;
111:14776–81
26.
ComerfordKMWallaceTJKarhausenJLouisNAMontaltoMCColganSP.Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res2002;
62:3387–94
27.
FrezzaCZhengLTennantDAPapkovskyDBHedleyBAKalnaGWatsonDGGottliebE.Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS One2011;
6:e24411
ZhangHGaoPFukudaRKumarGKrishnamacharyBZellerKIDangCVSemenzaGL.HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell2007;
11:407–20
30.
PeckBFerberECSchulzeA.Antagonism between FOXO and MYC regulates cellular powerhouse. Front Oncol2013;
3:96
31.
GordanJDBertoutJAHuCJDiehlJASimonMC.HIF-2alpha promotes hypoxic cell proliferation by enhancing c-Myc transcriptional activity. Cancer Cell2007;
11:335–47
32.
GordanJDLalPDondetiVRLetreroRParekhKNOquendoCEGreenbergRAFlahertyKTRathmellWKKeithBSimonMCNathansonKL.HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell2008;
14:435–46
33.
AustinSSt-PierreJ.PGC1alpha and mitochondrial metabolism–emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci2012;
125:4963–71
34.
SemenzaGL.HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev2010;
20:51–6
35.
SemenzaGL.Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype. EMBO J2017;
36:252–9
36.
KimJWTchernyshyovISemenzaGLDangCV.HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab2006;
3:177–85
37.
PapandreouICairnsRAFontanaLLimALDenkoNC.HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab2006;
3:187–97
38.
FukudaRZhangHKimJWShimodaLDangCVSemenzaGL.HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell2007;
129:111–22
39.
QuailDFJoyceJA.Microenvironmental regulation of tumor progression and metastasis. Nat Med2013;
19:1423–37
40.
ErdoganBWebbDJ.Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans2017;
45:229–36
41.
LeBleuVSKalluriR.A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis Model Mech2018;
11.doi:10.1242/dmm.029447
42.
Peiris-PagèsMSotgiaFLisantiMP.Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells. Oncotarget2015;
6:10728–45
43.
XingFSaidouJWatabeK.Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci2010;
15:166–79
44.
Berdiel-AcerMSanz-PamplonaRCalonACuadrasDBerenguerASanjuanXPaulesMJSalazarRMorenoVBatlleEVillanuevaAMollevíDG.Differences between CAFs and their paired NCF from adjacent colonic mucosa reveal functional heterogeneity of CAFs, providing prognostic information. Mol Oncol2014;
8:1290–305
45.
LiJJiaZKongJZhangFFangSLiXLiWYangXLuoYLinBLiuT.Carcinoma-associated fibroblasts lead the invasion of salivary gland adenoid cystic carcinoma cells by creating an invasive track. PLoS One2016;
11:e0150247
46.
Branco-PriceCZhangNSchnelleMEvansCKatschinskiDMLiaoDElliesLJohnsonRS.Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success. Cancer Cell2012;
21:52–65
47.
ZhangDWangYShiZLiuJSunPHouXZhangJZhaoSZhouBPMiJ.Metabolic reprogramming of cancer-associated fibroblasts by IDH3alpha downregulation. Cell Rep2015;
10:1335–48
48.
YanYWangLFWangRF.Role of cancer-associated fibroblasts in invasion and metastasis of gastric cancer. World J Gastroenterol2015;
21:9717–26
49.
WanandiSINingsihSSAsikinHHoseaRNeolakaG.Metabolic interplay between tumour cells and cancer-associated fibroblasts (CAFs) under hypoxia versus normoxia. Malays J Med Sci2018;
25:7–16
50.
PavlidesSTsirigosAVeraIFlomenbergNFrankPGCasimiroMCWangCFortinaPAddyaSPestellRGMartinez-OutschoornUESotgiaFLisantiMP.Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the “reverse warburg effect”: a transcriptional informatics analysis with validation. Cell Cycle2010;
9:2201–19
51.
YoshidaGJ.Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res2015;
34:111
52.
LuPWeaverVMWerbZ.The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol2012;
196:395–406
53.
BhowmickNANeilsonEGMosesHL.Stromal fibroblasts in cancer initiation and progression. Nature2004;
432:332–7
54.
GilkesDMSemenzaGLWirtzD.Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer2014;
14:430–9
55.
KaiFLaklaiHWeaverVM.Force matters: biomechanical regulation of cell invasion and migration in disease. Trends Cell Biol2016;
26:486–97
56.
WolfKTe LindertMKrauseMAlexanderSTe RietJWillisALHoffmanRMFigdorCGWeissSJFriedlP.Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J Cell Biol2013;
201:1069–84
57.
HalbergNKhanTTrujilloMEWernstedt-AsterholmIAttieADSherwaniSWangZVLandskroner-EigerSDineenSMagalangUJBrekkenRASchererPE.Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol2009;
29:4467–83
58.
MoonJOWelchTPGonzalezFJCoppleBL.Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice. Am J Physiol Gastrointest Liver Physiol2009;
296:G582–92
59.
GilkesDMBajpaiSChaturvediPWirtzDSemenzaGL.Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J Biol Chem2013;
288:10819–29
60.
XiongGDengLZhuJRychahouPGXuR.Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition. BMC Cancer2014;
14:1
61.
Eisinger-MathasonTSZhangMQiuQSkuliNNakazawaMSKarakashevaTMucajVShayJEStangenbergLSadriNPureEYoonSSKirschDGSimonMC.Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov2013;
3:1190–205
62.
GilkesDMBajpaiSWongCCChaturvediPHubbiMEWirtzDSemenzaGL.Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. Mol Cancer Res2013;
11:456–66
63.
GilkesDMChaturvediPBajpaiSWongCCWeiHPitcairnSHubbiMEWirtzDSemenzaGL.Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Res2013;
73:3285–96
64.
BarkerHECoxTRErlerJT.The rationale for targeting the LOX family in cancer. Nat Rev Cancer2012;
12:540
65.
ErlerJTBennewithKLNicolauMDornhöferNKongCLeQ-TChiJ-TJeffreySSGiacciaAJ.Lysyl oxidase is essential for hypoxia-induced metastasis. Nature2006;
440:1222
66.
SchietkeRWarneckeCWackerISchodelJMoleDRCampeanVAmannKGoppelt-StruebeMBehrensJEckardtKUWiesenerMS.The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. J Biol Chem2010;
285:6658–69
67.
ZhaoHWangJKongXLiELiuYDuXKangZTangYKuangYYangZZhouYWangQ.CD47 promotes tumor invasion and metastasis in non-small cell lung cancer. Sci Rep2016;
6:29719
68.
ZhangHLuHXiangLBullenJWZhangCSamantaDGilkesDMHeJSemenzaGL.HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl Acad Sci U S A2015;
112:E6215–23
69.
OkazawaHMotegiSOhyamaNOhnishiHTomizawaTKanekoYOldenborgPAIshikawaOMatozakiT.Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J Immunol2005;
174:2004–11
70.
LiuXKwonHLiZFuYX.Is CD47 an innate immune checkpoint for tumor evasion?J Hematol Oncol2017;
10:12
71.
LewisJSLandersRJUnderwoodJCHarrisALLewisCE.Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol2000;
192:150–8
72.
HuangYYuanJRighiEKamounWSAncukiewiczMNezivarJSantosuossoMMartinJDMartinMRVianelloFLeblancPMunnLLHuangPDudaDGFukumuraDJainRKPoznanskyMC.Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A2012;
109:17561–6
73.
ClambeyETMcNameeENWestrichJAGloverLECampbellELJedlickaPde ZoetenEFCambierJCStenmarkKRColganSPEltzschigHK.Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci USA2012;
109:E2784–93
74.
BatesGJFoxSBHanCLeekRDGarciaJFHarrisALBanhamAH.Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol2006;
24:5373–80
75.
BarsoumIBSmallwoodCASiemensDRGrahamCH.A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res2014;
74:665–74
76.
Palsson-McDermottEMDyckLZaslonaZMenonDMcGettrickAFMillsKHGO’NeillLA.Pyruvate kinase M2 is required for the expression of the immune checkpoint PD-L1 in immune cells and tumors. Front Immunol2017;
8:1300
EltzschigHKThompsonLFKarhausenJCottaRJIblaJCRobsonSCColganSP.Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood2004;
104:3986–92
SynnestvedtKFurutaGTComerfordKMLouisNKarhausenJEltzschigHKHansenKRThompsonLFColganSP.Ecto-5’-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest2002;
110:993–1002
81.
DadrasSSPaulTBertonciniJBrownLFMuzikanskyAJacksonDGEllwangerUGarbeCMihmMCDetmarM.Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol2003;
162:1951–60
82.
MiyaharaMTanumaJSugiharaKSembaI.Tumor lymphangiogenesis correlates with lymph node metastasis and clinicopathologic parameters in oral squamous cell carcinoma. Cancer2007;
110:1287–94
83.
SkobeMHawighorstTJacksonDGPrevoRJanesLVelascoPRiccardiLAlitaloKClaffeyKDetmarM.Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med2001;
7:192–8
84.
OhtaYShridharVBrightRKKalemkerianGPDuWCarboneMWatanabeYPassHI.VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer1999;
81:54–61
85.
WeiRLvMLiFChengTZhangZJiangGZhouYGaoRWeiXLouJWuXLuoDMaXJiangJMaDXiL.Human CAFs promote lymphangiogenesis in ovarian cancer via the Hh-VEGF-C signaling axis. Oncotarget2017;
8:67315–28
86.
JiRC.Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis. Cancer Lett2014;
346:6–16
87.
SchoppmannSFFenzlASchindlMBachleitner-HofmannTNagyKGnantMHorvatRJakeszRBirnerP.Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res Treat2006;
99:135–41
88.
KaramanSDetmarM.Mechanisms of lymphatic metastasis. J Clin Invest2014;
124:922–8
89.
WeichandBPoppRDziumblaSMoraJStrackEElwakeelEFrankACScholichKPierreSSyedSNOleschCRinglebJOrenBDoringCSavaiRJungMvon KnethenALevkauBFlemingIWeigertABruneB.S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1beta. J Exp Med2017;
214:2695–713
90.
LiSLiQ.Cancer stem cells, lymphangiogenesis, and lymphatic metastasis. Cancer Lett2015;
357:438–47
91.
SemenzaGL.Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene2013;
32:4057–63
92.
LiangXYangDHuJHaoXGaoJMaoZ.Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res2008;
28:1659–66
93.
SchitoLReySTafaniMZhangHWongCCRussoARussoMASemenzaGL.Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci U S A2012;
109:E2707–16
94.
HeoKKimYHSungHJLiHYYooCWKimJYParkJYLeeULNamBHKimEOKimSYLeeSHParkJBChoiSW.Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients. Oral Oncol2012;
48:500–6
95.
BertaJHodaMALaszloVRozsasAGarayTTorokSGruschMBergerWPakuSRenyi-VamosFMasriBTovariJGrogerMKlepetkoWHegedusBDomeB.Apelin promotes lymphangiogenesis and lymph node metastasis. Oncotarget2014;
5:4426–37
96.
Michiels C, Minet E, Michel G, Mottet D, Piret JP and Raes M. HIF-1 and AP-1 Cooperate to Increase Gene Expression in Hypoxia: Role of MAP Kinases. IUBMB Life 2001;52(1-2):49–53
97.
Bandyopadhyay RS, Phelan M, Faller DV. Hypoxia induces AP-1-regulated genes and AP-1 transcription factor binding in human endothelial and other cell types. Biochimica et Biophysica Acta 1995;1264(1):72–78
98.
PatelVMarshCADorsamRTMikelisCMMasedunskasAAmornphimolthamPNathanCASinghBWeigertRMolinoloAAGutkindJS.Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res2011;
71:7103–12
99.
GimbroneMAJr.LeapmanSBCotranRSFolkmanJ.Tumor dormancy in vivo by prevention of neovascularization. J Exp Med1972;
136:261–76
100.
KrockBLSkuliNSimonMC.Hypoxia-induced angiogenesis: good and evil. Genes Cancer2011;
2:1117–33
101.
ForsytheJAJiangBHIyerNVAganiFLeungSWKoosRDSemenzaGL.Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol1996;
16:4604–13
102.
LinCMcGoughRAswadBBlockJATerekR.Hypoxia induces HIF-1α and VEGF expression in chondrosarcoma cells and chondrocytes.2004;
22:1175–81
103.
Cejudo-MartinPMorales-RuizMRosJNavasaMFernandez-VaroGFusterJRiveraFArroyoVRodesJJimenezW.Hypoxia is an inducer of vasodilator agents in peritoneal macrophages of cirrhotic patients. Hepatology2002;
36:1172–9
104.
DesbailletsIDiserensACTriboletNHamouMFVan MeirEG.Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med1997;
186:1201–12
105.
HielscherAQiuCPorterfieldJSmithQGerechtS.Hypoxia affects the structure of breast cancer Cell-Derived matrix to support angiogenic responses of endothelial cells. J Carcinogen Mutagene2013;005
106.
ChungASFerraraN.Targeting the tumor microenvironment with SRC kinase inhibition. Clin Cancer Res2010;
16:775–7
107.
FolkmanJ.Tumor angiogenesis: therapeutic implications. N Engl J Med1971;
285:1182–6
108.
GiantonioBJCatalanoPJMeropolNJO’DwyerPJMitchellEPAlbertsSRSchwartzMABensonAB.Eastern cooperative oncology group study E. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern cooperative oncology group study E3200. J Clin Oncol2007;
25:1539–44
109.
OkinesACunninghamD.Current perspective: bevacizumab in colorectal cancer – a time for reappraisal?Eur J Cancer2009;
45:2452–61
110.
BergersGHanahanD.Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer2008;
8:592–603
111.
VasudevNSReynoldsAR.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis2014;
17:471–94
112.
CasanovasOHicklinDJBergersGHanahanD.Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell2005;
8:299–309
113.
FernandoNTKochMRothrockCGolloglyLKD’AmorePARyeomSYoonSS.Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res2008;
14:1529–39
114.
BertoliniFMancusoPShakedYKerbelRS.Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today2007;
12:806–12
115.
ThieryJPAcloqueHHuangRYNietoMA.Epithelial-mesenchymal transitions in development and disease. Cell2009;
139:871–90
116.
EbosJMLeeCRCruz-MunozWBjarnasonGAChristensenJGKerbelRS.Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell2009;
15:232–9
117.
Paez-RibesMAllenEHudockJTakedaTOkuyamaHVinalsFInoueMBergersGHanahanDCasanovasO.Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell2009;
15:220–31
118.
JingXYangFShaoCWeiKXieMShenHShuY.Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer2019;
18:157
119.
BalukPHashizumeHMcDonaldDM.Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev2005;
15:102–11
120.
MazzoneMDettoriDLeite de OliveiraRLogesSSchmidtTJonckxBTianYMLanahanAAPollardPRuiz de AlmodovarCDe SmetFVinckierSAragonesJDebackereKLuttunAWynsSJordanBPisacaneAGallezBLampugnaniMGDejanaESimonsMRatcliffePMaxwellPCarmelietP.Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell2009;
136:839–51
121.
OzawaMGYaoVJChantheryYHTroncosoPUemuraAVarnerASKasmanIMPasqualiniRArapWMcDonaldDM.Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma. Cancer2005;
104:2104–15
122.
HamzahJJugoldMKiesslingFRigbyPManzurMMartiHHRabieTKadenSGroneHJHammerlingGJArnoldBGanssR.Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature2008;
453:410–4
123.
JainRK.Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell2014;
26:605–22
124.
MoellerBJRichardsonRADewhirstMW.Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastas Rev2007;
26:241–8
125.
CarmelietPJainRK.Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov2011;
10:417–27
126.
JainRKDudaDGClarkJWLoefflerJS.Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol2006;
3:24–40
127.
JainRK.Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med2001;
7:987–9
128.
JainRK.Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science2005;
307:58–62
129.
YuanFChenYDellianMSafabakhshNFerraraNJainRK.Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A1996;
93:14765–70
130.
IzumiYXuLdi TomasoEFukumuraDJainRK.Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature2002;
416:279–80
131.
LongleyDBJohnstonPG.Molecular mechanisms of drug resistance. J Pathol2005;
205:275–92
132.
GottesmanMMFojoTBatesSE.Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer2002;
2:48–58
133.
ThomasHColeyHM.Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control2003;
10:159–65
134.
AmbudkarSVDeySHrycynaCARamachandraMPastanIGottesmanMM.Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol1999;
39:361–98
135.
ChoiCH.ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int2005;
5:30
136.
DoyleLAYangWAbruzzoLVKrogmannTGaoYRishiAKRossDD.A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A1998;
95:15665–70
137.
RobeyRWShuklaSSteadmanKObrzutTFinleyEMAmbudkarSVBatesSE.Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure. Mol Cancer Ther2007;
6:1877–85
138.
BhatavdekarJMPatelDDChikhlikarPRTrivediTIGosaliaNMGhoshNShahNGVoraHHSutharTP.Overexpression of CD44: a useful independent predictor of prognosis in patients with colorectal carcinomas. Ann Surg Oncol1998;
5:495–501
139.
DoktorovaHHrabetaJKhalilMAEckschlagerT.Hypoxia-induced chemoresistance in cancer cells: the role of not only HIF-1. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub2015;
159:166–77
140.
LiuLNingXSunLZhangHShiYGuoCHanSLiuJSunSHanZWuKFanD.Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci2008;
99:121–8
141.
SongXLiuXChiWLiuYWeiLWangXYuJ.Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol2006;
58:776–84
142.
DaijoHKaiSTanakaTWakamatsuTKishimotoSSuzukiKHaradaHTakabuchiSAdachiTFukudaKHirotaK.Fentanyl activates hypoxia-inducible factor 1 in neuronal SH-SY5Y cells and mice under non-hypoxic conditions in a mu-opioid receptor-dependent manner. Eur J Pharmacol2011;
667:144–52
143.
LiDWDongPWangFChenXWXuCZZhouL.Hypoxia induced multidrug resistance of laryngeal cancer cells via hypoxia-inducible factor-1alpha. Asian Pacific J Cancer Prevent2013;
14:4853–8
144.
XuanYHurHHamIHYunJLeeJYShimWKimYBLeeGHanSUChoYK.Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism. Exp Cell Res2014;
321:219–30
145.
ZhouSF.Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica2008;
38:802–32
SullivanRGrahamCH.Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol Cancer Ther2009;
8:1702–13
148.
GeXPanMHWangLLiWJiangCHeJAbouzidKLiuLZShiZJiangBH.Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/bad/bax axis. Cell Death Dis2018;
9:1128
149.
LiuXWSuYZhuHCaoJDingWJZhaoYCHeQJYangB.HIF-1alpha-dependent autophagy protects HeLa cells from fenretinide (4-HPR)-induced apoptosis in hypoxia. Pharmacol Res2010;
62:416–25
SchnitzerSESchmidTZhouJBruneB.Hypoxia and HIF-1alpha protect A549 cells from drug-induced apoptosis. Cell Death Differ2006;
13:1611–3
152.
CoffeyRNMorrisseyCTaylorCTFitzpatrickJMWatsonRW.Resistance to caspase-dependent, hypoxia-induced apoptosis is not hypoxia-inducible factor-1 alpha mediated in prostate carcinoma cells. Cancer2005;
103:1363–74
153.
RohwerNDameCHaugstetterAWiedenmannBDetjenKSchmittCACramerT.Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One2010;
5:e12038
154.
OhnoT.Particle radiotherapy with carbon ion beams. EPMA J2013;
4:9
155.
GrimesDRPartridgeM.A mechanistic investigation of the oxygen fixation hypothesis and oxygen enhancement ratio. Biomed Phys Eng Exp2015;
1:045209
156.
StadlerPBeckerAFeldmannHJHansgenGDunstJWurschmidtFMollsM.Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys1999;
44:749–54
157.
BrizelDMScullySPHarrelsonJMLayfieldLJBeanJMProsnitzLRDewhirstMW.Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res1996;
56:941–3 [Database
158.
LuHSamantaDXiangLZhangHHuHChenIBullenJWSemenzaGL.Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci U S A2015;
112:E4600–9
PalmerLAGastonBJohnsRA.Normoxic stabilization of hypoxia-inducible factor-1 expression and activity: redox-dependent effect of nitrogen oxides. Mol Pharmacol2000;
58:1197–203
162.
VerovskiVNVan den BergeDLSoeteGABolsBLStormeGA.Intrinsic radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside. Br J Cancer1996;
74:1734–42
163.
IllumHWangDHDowellJEHittsonWJTorrisiJRMeyerJHuertaS.Phase I dose escalation trial of nitroglycerin in addition to 5-fluorouracil and radiation therapy for neoadjuvant treatment of operable rectal cancer. Surgery2015;
158:460–5
164.
JanssensMYVan den BergeDLVerovskiVNMonsaertCStormeGA.Activation of inducible nitric oxide synthase results in nitric oxide-mediated radiosensitization of hypoxic EMT-6 tumor cells. Cancer Res1998;
58:5646–8
165.
GriffinRJMakepeaceCMHurWJSongCW.Radiosensitization of hypoxic tumor cells in vitro by nitric oxide. Int J Radiat Oncol Biol Phys1996;
36:377–83
166.
BumpEAYuNYBrownJM.Radiosensitization of hypoxic tumor cells by depletion of intracellular glutathione. Science1982;
217:544–5
167.
HeldKDEppERClarkEPBiaglowJE.Effect of dimethyl fumarate on the radiation sensitivity of mammalian cells in vitro. Radiat Res1988;
115:495–502
168.
RodmanSNSpenceJMRonnfeldtTJZhuYSolstSRO’NeillRAAllenBGGuanXSpitzDRFathMA.Enhancement of radiation response in breast cancer stem cells by inhibition of thioredoxin- and glutathione-dependent metabolism. Radiat Res2016;
186:385–95
169.
WangHBouzakouraSde MeySJiangHLawKDufaitICorbetCVerovskiVGevaertTFeronOVan den BergeDStormeGDe RidderM.Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species. Oncotarget2017;
8:35728–42
170.
SunLMoritakeTItoKMatsumotoYYasuiHNakagawaHHirayamaAInanamiOTsuboiK.Metabolic analysis of radioresistant medulloblastoma stem-like clones and potential therapeutic targets. PLoS One2017;
12:e0176162
171.
MaggiorellaLWenBFrascognaVOpolonPBourhisJDeutschE.Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model. Anticancer Res2005;
25:4357–62
172.
ZannellaVEDal PraAMuaddiHMcKeeTDStapletonSSykesJGlicksmanRChaibSZamiaraPMilosevicMWoutersBGBristowRGKoritzinskyM.Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res2013;
19:6741–50
173.
ZhangXDChenJLuoZWuDShenXSongSSSunYMLiuPXZhaoJHuoSFanSFanFLiangXJXieJ.Enhanced tumor accumulation of Sub-2 nm gold nanoclusters for cancer radiation therapy. Adv Healthcare Mater2014;
3:133–41
174.
ChenBZhangMXingDFengY.Atorvastatin enhances radiosensitivity in hypoxia-induced prostate cancer cells related with HIF-1alpha inhibition. Biosci Rep2017;
37. doi:10.1042/BSR20170340
175.
LeeDEAlhallakKJenkinsSVVargasIGreeneNPQuinnKPGriffinRJDingsRPMRajaramN.A radiosensitizing inhibitor of HIF-1 alters the optical redox state of human lung cancer cells in vitro. Sci Rep2018;
8:8815
